Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy (Q37780712)

23 August 2017

Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy (English)

1 reference

23 August 2017

Bernd Kaina

1

1 reference

PubMed ID

20717836

23 August 2017

Geoffrey P Margison

series ordinal

2

1 reference

PubMed ID

20717836

23 August 2017

Markus Christmann

series ordinal

3

1 reference

23 August 2017

18 August 2010

1 reference

Cellular and Molecular Life Sciences

23 August 2017

1 reference

23 August 2017

67

1 reference

23 August 2017

21

1 reference

23 August 2017

3663-3681

1 reference

https://scigraph.springernature.com/pub.10.1007/s00018-010-0491-7

23 August 2017

0 references

cites work

DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal

1 reference

https://api.crossref.org/works/10.1007%2FS00018-010-0491-7

Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-010-0491-7

Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-010-0491-7

Repair of O(6)-methylguanine is not affected by thymine base pairing and the presence of MMR proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-010-0491-7

O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-010-0491-7

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-010-0491-7

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

21 January 2018

1 reference

12 December 2020

Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU

1 reference

12 December 2020

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

1 reference

12 December 2020

Mechanisms of human DNA repair: an update

1 reference

12 December 2020

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

1 reference

12 December 2020

O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings

1 reference

12 December 2020

Alkylation of rat brain nucleic acids by N-methyl-N-nitrosourea and methyl methanesulphonate.

1 reference

12 December 2020

Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model

1 reference

12 December 2020

O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas

1 reference

12 December 2020

Crystal structure of a suicidal DNA repair protein: the Ada O6-methylguanine-DNA methyltransferase from E. coli

1 reference

12 December 2020

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

1 reference

12 December 2020

Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

1 reference

12 December 2020

DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.

1 reference

12 December 2020

Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector

1 reference

12 December 2020

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

1 reference

12 December 2020

Monosaccharide-linked inhibitors of O(6)-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships

1 reference

12 December 2020

Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death

1 reference

12 December 2020

Over-expression of facilitative glucose transporter genes in human cancer.

1 reference

12 December 2020

Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K).

1 reference

12 December 2020

Variability and regulation of O6-alkylguanine-DNA alkyltransferase

1 reference

12 December 2020

Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study

1 reference

12 December 2020

Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide

1 reference

12 December 2020

Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks.

1 reference

12 December 2020

Long-time expression of DNA repair enzymes MGMT and APE in human peripheral blood mononuclear cells.

1 reference

12 December 2020

Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo

1 reference

12 December 2020

Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs

1 reference

12 December 2020

Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.

1 reference

12 December 2020

Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia

1 reference

12 December 2020

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

1 reference

12 December 2020

Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer

1 reference

12 December 2020

Phase II study of extended-dose temozolomide in patients with melanoma

1 reference

12 December 2020

MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.

1 reference

12 December 2020

Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU

1 reference

12 December 2020

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

1 reference

12 December 2020

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

1 reference

12 December 2020

Mutagenic potential of temozolomide in bone marrow cells in vivo

1 reference

12 December 2020

Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report

1 reference

12 December 2020

Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase

1 reference

12 December 2020

Identification of the cross-link between human O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA

1 reference

12 December 2020

Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone.

1 reference

12 December 2020

O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.

1 reference

12 December 2020

1 reference

12 December 2020

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

12 December 2020

DNA repair in resistance to alkylating anticancer drugs

1 reference

12 December 2020

Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo.

1 reference

12 December 2020

Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine

1 reference

12 December 2020

Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells

1 reference

12 December 2020

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

1 reference

12 December 2020

Secondary Ph+ acute lymphoblastic leukemia after temozolomide

1 reference

12 December 2020

Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts

1 reference

12 December 2020

Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea

1 reference

12 December 2020

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

12 December 2020

O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.

1 reference

12 December 2020

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.

1 reference

12 December 2020

Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling

1 reference

12 December 2020

Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents

1 reference

12 December 2020

Experimental evaluation of potential anticancer agents. VI. Anatomical distribution of leukemic cells and failure of chemotherapy

1 reference

12 December 2020

O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.

1 reference

12 December 2020

Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine

1 reference

12 December 2020

Gene transfer to suppress bone marrow alkylation sensitivity.

1 reference

12 December 2020

O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues

1 reference

12 December 2020

Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes

1 reference

12 December 2020

O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.

1 reference

12 December 2020

Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.

1 reference

12 December 2020

O6-benzylguanine-mediated enhancement of chemotherapy.

1 reference

12 December 2020

Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT).

1 reference

12 December 2020

The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage

1 reference

12 December 2020

Human liver oxidative metabolism of O6-benzylguanine

1 reference

12 December 2020

Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.

1 reference

12 December 2020

Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines.

1 reference

12 December 2020

Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate

1 reference

12 December 2020

Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases

1 reference

12 December 2020

Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells

1 reference

12 December 2020

Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine

1 reference

12 December 2020

O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.

1 reference

12 December 2020

Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine

1 reference

12 December 2020

Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.

1 reference

12 December 2020

Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy

1 reference

12 December 2020

Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism.

1 reference

12 December 2020

Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model

1 reference

12 December 2020

DNA double-strand breaks trigger apoptosis in p53-deficient fibroblasts

1 reference

12 December 2020

Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate

1 reference

12 December 2020

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

12 December 2020

Protein phosphorylation is a regulatory mechanism for O6-alkylguanine-DNA alkyltransferase in human brain tumor cells

1 reference

12 December 2020

Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib

1 reference

12 December 2020

Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer

1 reference

12 December 2020

Inactivation of O(6)-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors

1 reference

12 December 2020

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

1 reference

12 December 2020

Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial

1 reference

12 December 2020

Specific recognition of O6-methylguanine in DNA by active site mutants of human O6-methylguanine-DNA methyltransferase

1 reference

12 December 2020

Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue.

1 reference

12 December 2020

O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts

1 reference

12 December 2020

Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase

1 reference

12 December 2020

Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine

1 reference

12 December 2020

DNA repair protein O6-alkylguanine-DNA alkyltransferase is phosphorylated by two distinct and novel protein kinases in human brain tumour cells

1 reference

12 December 2020

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine

1 reference

12 December 2020

Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma

1 reference

12 December 2020

Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine

1 reference

12 December 2020

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

1 reference

12 December 2020

Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents

1 reference

12 December 2020

Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea

1 reference

12 December 2020

Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.

1 reference

12 December 2020

Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent

1 reference

12 December 2020

Exhaustion and recovery of repair excision of O6-methylguanine from rat liver DNA

1 reference

12 December 2020

Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.

1 reference

12 December 2020

Why do cancer cells have such a high glycolytic rate?

1 reference

12 December 2020

Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.

1 reference

12 December 2020

MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

1 reference

12 December 2020

O6-methylguanine-DNA methyltransferase in human brain tumors detected by activity assay and monoclonal antibodies.

1 reference

12 December 2020

Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine

1 reference

12 December 2020

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer

1 reference

12 December 2020

Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.

1 reference

12 December 2020

In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector

1 reference

12 December 2020

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

1 reference

12 December 2020

Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates

1 reference

12 December 2020

Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human O6-alkylguanine-DNA-alkyltransferase

1 reference

12 December 2020

Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts.

1 reference

12 December 2020

O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.

1 reference

12 December 2020

A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma

1 reference

12 December 2020

The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine

1 reference

12 December 2020

Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice

1 reference

12 December 2020

Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents

1 reference

12 December 2020

Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base.

1 reference

12 December 2020

Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.

1 reference

12 December 2020

Genomic and molecular profiling predicts response to temozolomide in melanoma

1 reference

12 December 2020

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme

1 reference

12 December 2020

Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.

1 reference

12 December 2020

Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study

1 reference

12 December 2020

2-amino-O4-benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase

1 reference

12 December 2020

Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea

1 reference

12 December 2020

Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro

1 reference

12 December 2020

Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma

1 reference

12 December 2020

Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells.

1 reference

12 December 2020

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

1 reference

12 December 2020

10.1007/S00018-010-0491-7

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20717836